about
An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencingAcute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.Longitudinal in vivo susceptibility contrast MRI measurements of LS174T colorectal liver metastasis in nude mice.The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaLack of correlation between residual radiation-induced DNA damage, in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients.Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging.Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude ratEvaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.False-negative MRI biomarkers of tumour response to targeted cancer therapeuticsDistinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissuesATM and ATR as therapeutic targets in cancer.Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.Replication stress and chromatin context link ATM activation to a role in DNA replication.Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancerVandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.Potential antagonism of tubulin-binding anticancer agents in combination therapies.In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
P50
Q28390823-0997DBEF-F197-48A2-A087-FAC3B60C37E7Q33217481-84F34C76-A1BE-49FE-B803-C0A903772BF4Q33236142-B623782C-BFE9-46CD-AC81-A151546A0818Q33299990-35107C8B-5378-4A0B-A38F-28FBB428E780Q33386365-C1C911A5-4F92-4790-805C-7E6FB4B538D0Q33514437-7889903A-A885-40B3-9B81-DCA476A28985Q33541467-05732A4F-1585-4F1D-BEC1-3D20B662EFFEQ33816112-B7483BA5-B86A-4A69-8915-C7A231CB44C7Q34104025-6B9569A5-F7F0-4E32-B5EA-74F2CE7993F0Q34105344-602DB734-A329-49D8-80FF-3FAF5C64D95DQ34145257-796EB3C1-177C-45F1-B0CC-B17059E9637FQ34273077-F6EE7BA3-0389-4567-A81A-22791ABB1101Q34578277-F53F7D5E-7443-4349-AEB5-3E47B56E672BQ35939630-36A8C738-EC27-4636-B170-610B38A23FAEQ36270034-3D6813D1-1BC1-41C4-847D-C060FDD3E5B7Q36275644-72B0D665-A5BD-4A62-8416-B09A6145A280Q36563979-6E909DC4-B467-4BED-8CEF-C608B5EA6A7EQ36611295-2FD33D09-3986-4310-90F8-C9DF04D89B17Q36696611-C4D19B81-418E-4E63-8657-9755CA9DB58CQ36869865-BF324C3F-88F5-4F67-B716-456C28D53131Q36943978-119D66BD-A769-4003-8756-2C0B3014B4ECQ37287554-BFDEFDB4-2FEF-41C2-A03D-66922EB90819Q38289832-D2A8BF0F-86D8-4CF4-967F-B305FE085D04Q39017559-8ECAA16F-2700-4882-B8CF-89C05A719D6BQ39057569-46CC1A7D-8311-4645-B0CB-0226C2C19E09Q39060826-7B67EA47-9016-4821-85FA-81863B1B7CACQ39068918-4C863826-640D-4501-BAEB-F8F63F333507Q39414954-81CE9624-83B8-4DA8-A15D-A0768A2D8973Q39549482-91581521-8658-4347-836B-81481DC59417Q39620696-E7EE9567-97FC-4669-AD8E-3F671923A340Q39644790-330254B6-F575-4B97-844F-744A567064DEQ39683766-BD7DB35B-A505-41C0-A16F-0B1EAC575074Q39951371-BCE64D41-1673-4194-AEE1-5C64D1FCB3A7Q39951743-CFA04C4B-166C-4735-95E4-5AEFA65E4A30Q39998844-B33A1739-C80E-4FEE-BA54-D513241D1120Q40338967-B6E7B465-2E53-4ED1-B287-0AF87F68B0B2Q40427890-6D3818B7-5B0F-4D5B-914F-F981564E9197Q40438018-5FEA0FE8-3431-40E3-BDAD-61C99F40A464Q40498095-E8819203-EE91-4688-AA88-164B2467BAD0Q40550186-D36DE08C-188B-4516-8611-B1CD9750E194
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-6241-7969
@en
name
Anderson J Ryan
@ast
Anderson J Ryan
@en
Anderson J Ryan
@nl
type
label
Anderson J Ryan
@ast
Anderson J Ryan
@en
Anderson J Ryan
@nl
prefLabel
Anderson J Ryan
@ast
Anderson J Ryan
@en
Anderson J Ryan
@nl
P106
P31
P496
0000-0001-6241-7969